





Institutionalizing Community Health Conference

27-30 March 2017 | Johannesburg, South Africa





#HealthForAll ichc2017.org

Session 32: Selected topics in implementation research for community-based service delivery

Expanding Community-Based Access to Injectable Contraception: A Global Overview

Leigh Wynne, FHI 360 Advancing Partners & Communities Project Institutionalizing Community Health Conference, March 2017









Outline

- 1. Rationale, Global Guidance and Current Status for Community-Based Access to Injectables (CBA2I)
- 2. Uganda Case Study: DMPA SubQ Introduction
- 3. Next Frontiers for CBA2I
 - 2. Drug Shops
 - 3. Home and Self Injection
- 4. Q&A






Rationale, Global Guidance and Current Status for Community Based Access to Injectables






Countries with a Critical Shortage of Doctors, Nurses, and Midwives



Current Use of Injectable Contraception Among Married Women 15-49



Source: DHS Surveys as of Aug 2012

WHO Global Guidance

- Appropriately trained CHWs can
 - screen clients
 - administer injectables
 - counsel on side effects
- National policies should support introduction and scale-up



Conclusions from a Technical Consultation

Community-Based Health Workers Can Safely and Effectively Administer Injectable Contraceptives

In June 2009, a technical consultation held at the World Health Organization (WHO) in Geneva concluded that evidence supports the introduction, continuation, and scale-up of community-based provision of progestin-only injectable contraceptives. The group of 30 technical and programme experts reviewed scientific and programmatic experience, which largely focused on the progestin-only injectable, depot-medroxyprogesterone acetate (DMPA). (See box inside on terminology.) The experts found that community-based provision of progestin-only injectable contraceptives by appropriately trained community health workers (CHWs) is safe, effective, and acceptable. Such services should be part of a family planning programme offering a range of contraceptive methods.

Need for Injectable Contraception Expands

Currently, 35 million women worldwide use injectable contraception to prevent pregnancy, twice as many as a decade ago. In sub-Saharan Africa, more than one-third of users of modern contraceptives rely on injectables, more than any other modern contraceptive method. Even to, most countries report levels of unmet need for injectables between 25 percent and \$0 percent of women who intend to use contraception in the future (see box inside on unmet need). While other temporary methods, such as pills and condoms, are available through community-based distribution, pharmacies, and commercial outlets, injectables, are available primarily through clinics.

Injectables are among the most effective contraceptive methods, after intrauterine devices, implants, and sterilization. The majority of injectable clients use DMPA. an intramuscular injection of 150 mg given every three months. Most women can safely use a progestin-only injectable. WHO has identified only a few medical conditions that limit or prohibit its use.¹ Prior to initiating use, providers need to be able to screen clients for pregnancy and for medical eligibility. In addition, they should be able to provide injections safely and to inform women about delayed return to fertility and potential side effects, including vaginal bleeding irregularities, amenorihea, and weight gain.

Task shifting, also referred to as task shaing, has been used successfully to address the otikical brotoge of medical professionals and to expand access to a ninge of health services. With task sharing, a concept endorsed by WHO, providers with less medical or parametical training can deliver some of the symme services with the same quality as providen with more training in the lost decade. CHWs have provided DWK is more than a dozen countries, including Alghanistan, Bangladeth, Bolivia, Guatemula, Ethiopia, Haiti, Madaganca, Malawi, Nepal, and Uganda. In an effort to inform future policies and

In an effort to interminuture poinces and programmes, WHO, the U.S. Agency for International Development (USAID), and Family Health International (FHE) convened the Technical Consultation on Expanding Access to Injectable Contraception, held on 15-17 June 2009.

http://www.k4health.org/toolkits/cba2i/conclusions





WHO recommendations on task sharing family planning (2012)

 WHO recommended as already widely recognised and established practice

 WHO recommended


 WHO recommended with targeted monitoring and evaluation

 WHO recommended only in the context of rigorous research

 WHO recommends against

	LHWs	Auxiliary Nurses	Auxiliary Midwives	Nurses	Midwives	Associate Clinicians	Doctors
Tubal Ligation							
Vasectomy							
IUDs							
Implants							
Injectables							
OCPs & Condoms							

Status of CBA2I in Africa - 2017



Components of Successful Introduction

- \checkmark Political will and MOH collaboration
 - Champion leading advocacy
 - FP Technical Working Group
- ✓ Supportive policies important (but not essential for piloting; you can often get a waiver)
- \checkmark Community ownership
- \checkmark Harmonization with existing health structure
- ✓ Steady supply of commodities
- ✓ Strong M&E system implemented early
- ✓ Partnerships









Community-Based Access to Injectable Contraceptives

English

🚘 Home	
🖸 About	
All Resources	
Global Evidence	0
Country Experiences	0
Advocate	
Pilot	
Implement	o
Scale Up	
Partners	0
en Français	

www.k4health.org/toolkits/cba2i

https://www.globalhealthlearning.org/course/communitybased-family-planning-0

Uganda Case Study: DMPA SubQ Introduction





How are DMPA IM and DMPA SubQ different?

Feature	DMPA IM	DMPA SubQ (e.g., Sayana Press)		
Mg/dose	150 mg	104 mg		
Package	Vial and syringe	Prefilled Uniject injection system		
Type of injection	Intramuscular (deep into the muscle)	Subcutaneous (in the fatty tissue under the skin)		
Where to inject	 Arm (deltoid muscle) Hip Buttocks 	 Anterior thigh (front of thigh) Abdomen Back of arm 		
Skin irritation	Skin irritation at injection site is not likely	Skin may be a little irritated at injection site		

Why is DMPA SubQ a "game changer"?

- Specifically developed to address logistics and safety challenges of widespread distribution in lowresource settings
- Potential for self-injection, which may:
 - increase user autonomy and lower discontinuation rates
 - decrease operational costs, improve efficient use of providers' time, expand CHWs' role
 - reduce opportunity costs for users







Factors that led to research uptake of CHW provision of DMPA SubQ

- Product easy to use
- Decision to adopt happened before the study began
- Focus of the research was operational
- National Drug Authority engaged from the start



Photo credit: Patricia Wamala, FHI 360





Factors that led to research uptake, cont.


- The study itself was designed to support introduction and scaleup
 - Training materials from the study were already developed and approved by the MOH
 - Master trainers from the study were used to train CHWs for initial scale-up
 - CHW trained during study continued to provide SP in their communities
 - Dissemination and uptake of the findings facilitated by active Sayana Press Working Group



Photo credit: Laura Wando, WellShare International







Uganda introduction strategy

♣PATH

Challenges to Introduction in Uganda

- Product donated from BMGF. Long term this is not sustainable
- Product expired and it had to be pulled
- Training health workers challenges because of frequent transfers
- Distribution contract through the auxiliary supply chain PATH/Gates are using is costly and some partners opt out
- High demand at time of introduction can result in stockouts





Next Frontiers for CBA2I

- Drug Shops
- Home and Self-Injection



Photo credit: Tracy Orr, FHI 360











Institutionalizing Community Health Conference

27-30 March 2017 | Johannesburg, South Africa





#HealthForAll ichc2017.org